» Articles » PMID: 36268052

Identification of Risk Genes for Alzheimer's Disease by Gene Embedding

Overview
Journal Cell Genom
Date 2022 Oct 21
PMID 36268052
Authors
Affiliations
Soon will be listed here.
Abstract

Most disease-gene association methods do not account for gene-gene interactions, even though these play a crucial role in complex, polygenic diseases like Alzheimer's disease (AD). To discover new genes whose interactions may contribute to pathology, we introduce GeneEMBED. This approach compares the functional perturbations induced in gene interaction network neighborhoods by coding variants from disease versus healthy subjects. In two independent AD cohorts of 5,169 exomes and 969 genomes, GeneEMBED identified novel candidates. These genes were differentially expressed in AD brains and modulated neurological phenotypes in mice. Four that were differentially overexpressed and modified neurodegeneration are PLEC, UTRN, TP53, and POLD1. Notably, TP53 and POLD1 are involved in DNA break repair and inhibited by approved drugs. While these data show proof of concept in AD, GeneEMBED is a general approach that should be broadly applicable to identify genes relevant to risk mechanisms and therapy of other complex diseases.

Citing Articles

Alzheimer's Disease Sequencing Project Release 4 Whole Genome Sequencing Dataset.

Leung Y, Lee W, Kuzma A, Nicaretta H, Valladares O, Gangadharan P medRxiv. 2024; .

PMID: 39677464 PMC: 11643159. DOI: 10.1101/2024.12.03.24317000.


Multi-trait association analysis reveals shared genetic loci between Alzheimer's disease and cardiovascular traits.

Koskeridis F, Fancy N, Tan P, Meena D, Evangelou E, Elliott P Nat Commun. 2024; 15(1):9827.

PMID: 39537608 PMC: 11561119. DOI: 10.1038/s41467-024-53452-6.


Single-Cell Patch-Clamp/Proteomics of Human Alzheimer's Disease iPSC-Derived Excitatory Neurons Versus Isogenic Wild-Type Controls Suggests Novel Causation and Therapeutic Targets.

Ghatak S, Diedrich J, Talantova M, Bhadra N, Scott H, Sharma M Adv Sci (Weinh). 2024; 11(29):e2400545.

PMID: 38773714 PMC: 11304297. DOI: 10.1002/advs.202400545.


A review and analysis of key biomarkers in Alzheimer's disease.

Zhang Z, Liu X, Zhang S, Song Z, Lu K, Yang W Front Neurosci. 2024; 18:1358998.

PMID: 38445255 PMC: 10912539. DOI: 10.3389/fnins.2024.1358998.


Drug target prediction through deep learning functional representation of gene signatures.

Chen H, King F, Zhou B, Wang Y, Canedy C, Hayashi J Nat Commun. 2024; 15(1):1853.

PMID: 38424040 PMC: 10904399. DOI: 10.1038/s41467-024-46089-y.


References
1.
Leggio G, Torrisi S, Mastrogiacomo R, Mauro D, Chisari M, Devroye C . The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. Mol Psychiatry. 2019; 26(4):1272-1285. DOI: 10.1038/s41380-019-0511-4. View

2.
Onur T, Laitman A, Zhao H, Keyho R, Kim H, Wang J . Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis. Elife. 2021; 10. PMC: 8149125. DOI: 10.7554/eLife.64564. View

3.
Pavel M, Imarisio S, Menzies F, Jimenez-Sanchez M, Siddiqi F, Wu X . CCT complex restricts neuropathogenic protein aggregation via autophagy. Nat Commun. 2016; 7:13821. PMC: 5155164. DOI: 10.1038/ncomms13821. View

4.
Lisewski A, Quiros J, Ng C, Adikesavan A, Miura K, Putluri N . Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell. 2014; 158(4):916-928. PMC: 4167585. DOI: 10.1016/j.cell.2014.07.011. View

5.
Chumakov I, Nabirotchkin S, Cholet N, Milet A, Boucard A, Toulorge D . Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy. Sci Rep. 2015; 5:7608. PMC: 5378993. DOI: 10.1038/srep07608. View